HomeTOP STORIESSanuwave withdraws FY2026 revenue guidance amid CMS proposal implying 97610 reimbursement of... Sanuwave withdraws FY2026 revenue guidance amid CMS proposal implying 97610 reimbursement of $316.59 in 2027 By rogerjudd August 7, 2026 FacebookTwitterPinterestWhatsApp Post Content Previous articleTrulieve anticipates at least $225M in 2026 operating cash flow while raising capex outlook to $95MNext articleSan Francisco dad questioned by park rangers for teaching his own kids tennis at public court latest articles Amrize forecasts $12.5B-$12.7B 2026 revenue while targeting $3.1B-$3.2B adjusted EBITDA amid oil-driven cost inflation Dauch targets $10.6B-$10.8B sales and $1.36B-$1.425B EBITDA as integration run rate savings reach $70M New Jersey Opens Civil Rights Investigation Into Delaney Hall Schumer, Despite Party Tensions, Forges Ahead in Fight for Senate San Francisco dad questioned by park rangers for teaching his own kids tennis at public court Trulieve anticipates at least $225M in 2026 operating cash flow while raising capex outlook to $95M explore more Amrize forecasts $12.5B-$12.7B 2026 revenue while targeting $3.1B-$3.2B adjusted EBITDA amid oil-driven cost inflation Dauch targets $10.6B-$10.8B sales and $1.36B-$1.425B EBITDA as integration run rate savings reach $70M New Jersey Opens Civil Rights Investigation Into Delaney Hall Schumer, Despite Party Tensions, Forges Ahead in Fight for Senate San Francisco dad questioned by park rangers for teaching his own kids tennis at public court Trulieve anticipates at least $225M in 2026 operating cash flow while raising capex outlook to $95M
